Published by Erik Greb on October 5, 2009
under Biotech, Drug Delivery, R&D, Trends
When pipelines run dry, pharmaceutical companies are more likely to investigate alternative delivery methods as a way of distinguishing their drugs in the marketplace. In the past few weeks, I’ve noticed several intriguing delivery methods created by researchers around the world. I recently wrote about the new technique of encapsulating medicines in magnetite nanoparticles for repeated, long-term delivery. Along similar lines, scientists at Queen Mary, University of London have created “micro shuttles” that can be loaded with drugs and opened remotely. Read more »
Published by Erik Greb on June 29, 2009
under Drug Delivery, Formulation, Manufacturing, North America News, Regulation, Trends
Reports of teenagers’ pharm parties, Rush Limbaugh’s OxyContin addiction, and the questions surrounding Michael Jackson’s death have kept prescription-drug abuse in the public eye. By requiring manufacturers of opioid drugs to create risk evaluation and mitigation strategies, the US Food and Drug Administration is seeking to reduce opportunities for drug abuse while keeping the therapies available to patients who need them. One pharmaceutical company suggests that, in addition to regulatory solutions, drug abuse could be curbed using drug-delivery strategies. Read more »
Published by Erik Greb on June 8, 2009
under Manufacturing, North America News, Regulation, Trends
President Obama’s plan for lowering the cost of healthcare relies partly on ensuring that affordable generic drugs are available to patients. This strategy is not likely to be palatable to innovator companies, who have tried various ways of delaying generic drugs’ introduction to the market. Read more »
Published by Erik Greb on April 27, 2009
under Biotech, Industry conferences, Manufacturing, North America News, Products & Equipment, R&D, Regulation, Trends
Speakers’ comments at the Parenteral Drug Association’s Annual Meeting, held in Las Vegas on Apr. 20-24, 2009, reflected the crisis that pharmaceutical and biopharmaceutical industries face. Presenters alluded to a cloud of challenges (e.g., cost pressures, products that can be duplicated by competitors, and quality-control failures) that has been gathering for some time. Several speakers claimed that small- and large-molecule manufacturers must change now to survive in the short and long terms. But change how? Read more »
Published by Erik Greb on April 20, 2009
under Manufacturing, Regulation
Like everything else, drug products sometimes end up as waste. Lately I’ve tried to reduce the amount of waste I generate and dispose of it carefully. I’ve written before about how flushing unused drugs down the toilet, which was previously recommended, can harm the environment. But what’s the alternative? Read more »
Published by Erik Greb on March 30, 2009
under Analytics, Drug Delivery, Manufacturing, Regulation
As an editor for Pharmaceutical Technology, I often hear about novel drug-delivery mechanisms. Often they’re high-tech materials such as polymers, hydrogels, or nanoparticles. But a recent Associated Press story revealed a biological-based drug carrier that I hadn’t thought of: fish. Read more »
Published by Erik Greb on February 23, 2009
under Ingredients, Manufacturing, R&D, Trends
At the moment, the pharmaceutical industry is preoccupied with financial concerns, mainly because of patent expirations, weak pipelines, and our limping economy. But before the current crisis, many companies were devoting greater attention to minimizing the harmful environmental effects of their processes. What if there were a way to address these two concerns at once? Read more »
Published by Erik Greb on December 15, 2008
under North America News, Regulation, Trends
We’ve all seen unsuspecting movie characters laid low by poisoned drinks (as in “The Maltese Falcon”). Similar scenes were in my mind when I heard reports that trace levels of drugs had been found in American cities’ drinking water. That’s why I was happy to see that the Environmental Protection Agency (EPA) had begun to strengthen the regulation of discarded medicines. Read more »
Published by Erik Greb on March 24, 2008
under Analytics, Regulation
When I heard on the radio that tests had revealed trace levels of pharmaceuticals in New York City’s drinking water, I was alarmed. I drink a lot of water, and I take it for granted that it’s safe. I assume it’s been filtered, sterilized, treated, and tested so that it’s healthy and innocuous. Read more »
« Previous Page